PMID- 35729499
OWN - NLM
STAT- MEDLINE
DCOM- 20220623
LR  - 20220716
IS  - 1471-2261 (Electronic)
IS  - 1471-2261 (Linking)
VI  - 22
IP  - 1
DP  - 2022 Jun 21
TI  - The association between serum Sestrin2 and the risk of coronary heart disease in 
      patients with type 2 diabetes mellitus.
PG  - 281
LID - 10.1186/s12872-022-02727-1 [doi]
LID - 281
AB  - BACKGROUND: Coronary heart disease (CHD) is one of the most common causes of 
      morbidity and mortality in type 2 diabetes mellitus (T2DM). Oxidative stress is 
      one of the important contributors to the pathogenesis of CHD. Sestrin2 is a 
      stress-induced antioxidant protein that plays a important role in T2DM and CHD. 
      However, the relationship between serum Sestrin2 levels and T2DM with CHD remains 
      unclear. AIM: This study aimed to investigate the relationship between serum 
      Sestrin2 levels and CHD in patients with type 2 diabetes. METHODS: A total of 70 
      T2DM patients with CHD and 69 T2DM patients were enrolled in this study. Clinical 
      features and metabolic indices were identified. Serum Sestrin2 was measured by 
      ELISA. RESULTS: Serum Sestrin2 levels in T2DM-CHD groups were significantly lower 
      compared with the T2DM group (11.17 (9.79, 13.14) ng/mL vs 9.46 (8.34, 10.91) 
      ng/mL). Bivariate correlation analysis revealed that serum Sestrin2 levels were 
      negatively correlated with age (r = - 0.256, P = 0.002), BMI (r = - 0.206, 
      P = 0.015), FBG (r = - 0.261, P = 0.002) and Tyg index (r = - 0.207, P < 0.014). 
      Binary logistic regression suggested that low serum Sestrin2 levels were related 
      to the increased risk of T2DM-CHD (P < 0.05). In addition, the receiver operating 
      characteristic analysis revealed that the area under the curve of Sestrin2 was 
      0.724 (95% CI 0.641-0.808, P < 0.001) to predict T2DM-CHD patients (P < 0.001). 
      CONCLUSION: The Sestrin2 levels were highly associated with CHD in diabetes 
      patients. Serum Sestrin2 may be involved in the occurrence and development of 
      diabetic with CHD.
CI  - (c) 2022. The Author(s).
FAU - Tian, Xue
AU  - Tian X
AD  - Department of Endocrinology, Affiliated Hospital of Chengde Medical University, 
      Chengde, China.
FAU - Gao, Yu
AU  - Gao Y
AD  - Department of Endocrinology, Affiliated Hospital of Chengde Medical University, 
      Chengde, China. yugao815@163.com.
FAU - Zhong, Min
AU  - Zhong M
AD  - Department of Endocrinology, Affiliated Hospital of Chengde Medical University, 
      Chengde, China.
FAU - Kong, Mowei
AU  - Kong M
AD  - Department of Endocrinology, Affiliated Hospital of Chengde Medical University, 
      Chengde, China.
FAU - Zhao, Lihua
AU  - Zhao L
AD  - Department of Endocrinology, Affiliated Hospital of Chengde Medical University, 
      Chengde, China.
FAU - Feng, Zengbin
AU  - Feng Z
AD  - Department of Cardiology, Affiliated Hospital of Chengde Medical University, 
      Chengde, China.
FAU - Sun, Qitian
AU  - Sun Q
AD  - Department of Endocrinology, Affiliated Hospital of Chengde Medical University, 
      Chengde, China.
FAU - He, Jianqiu
AU  - He J
AD  - Department of Endocrinology, Affiliated Hospital of Chengde Medical University, 
      Chengde, China.
FAU - Liu, Xiaoyan
AU  - Liu X
AD  - Department of Endocrinology, Affiliated Hospital of Chengde Medical University, 
      Chengde, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220621
PL  - England
TA  - BMC Cardiovasc Disord
JT  - BMC cardiovascular disorders
JID - 100968539
SB  - IM
MH  - *Coronary Disease/complications/diagnosis/epidemiology
MH  - *Diabetes Mellitus, Type 2/complications/diagnosis
MH  - Humans
MH  - ROC Curve
MH  - Risk Factors
PMC - PMC9215095
OTO - NOTNLM
OT  - CHD
OT  - Oxidative stress
OT  - Sestrin2
OT  - Type 2 diabetes mellitus
COIS- No conflicting relationship exists for any author.
EDAT- 2022/06/22 06:00
MHDA- 2022/06/24 06:00
PMCR- 2022/06/21
CRDT- 2022/06/21 23:36
PHST- 2022/04/20 00:00 [received]
PHST- 2022/06/17 00:00 [accepted]
PHST- 2022/06/21 23:36 [entrez]
PHST- 2022/06/22 06:00 [pubmed]
PHST- 2022/06/24 06:00 [medline]
PHST- 2022/06/21 00:00 [pmc-release]
AID - 10.1186/s12872-022-02727-1 [pii]
AID - 2727 [pii]
AID - 10.1186/s12872-022-02727-1 [doi]
PST - epublish
SO  - BMC Cardiovasc Disord. 2022 Jun 21;22(1):281. doi: 10.1186/s12872-022-02727-1.